Exelixis Earnings
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$0.79
Exelixis earnings summary
Exelixis is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $0.79. In its most recent report on Aug 5, 2026 (Q2 2026), EXEL posted EPS of $0.82. Revenue for the quarter was $628.7 million.
Quarterly EPS is up 26.2% from the same quarter a year earlier. Across the last 16 reports, EXEL shares moved an average of 3.1% (in either direction) in the first trading session after results, rising 9 times and falling 6 times.
Summary generated from market data by MetaCap's automated system. Methodology
EXEL earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 5, 2026 | — | $0.82 | — | -5.2% |
| May 5, 2026 | — | $0.79 | — | +4.1% |
| Feb 10, 2026 | — | $0.89 | — | -0.7% |
| Nov 4, 2025 | — | $0.69 | — | +2.1% |
| Jul 28, 2025 | — | $0.65 | — | +1.2% |
| May 13, 2025 | — | $0.55 | — | -6.6% |
| Feb 11, 2025 | — | $0.47 | — | +5.3% |
| Oct 29, 2024 | — | $0.40 | — | +6.2% |
| Aug 6, 2024 | — | $0.77 | — | -2.3% |
| Apr 30, 2024 | — | $0.12 | — | -2.4% |
| Feb 6, 2024 | — | $0.28 | — | +1.3% |
| Nov 1, 2023 | — | $0.00 | — | 0.0% |
| Aug 1, 2023 | — | $0.25 | — | +6.2% |
| May 9, 2023 | — | $0.12 | — | +3.2% |
| Feb 7, 2023 | — | $-0.10 | — | -0.3% |
| Nov 1, 2022 | — | $0.23 | — | +2.1% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.